High-Energy Phosphates and Ischemic Heart Disease: From Bench to Bedside
The purpose of this review is to bridge the gap between clinical and basic research through providing a comprehensive and concise description of the cellular and molecular aspects of cardioprotective mechanisms and a critical evaluation of the clinical evidence of high-energy phosphates (HEPs) in is...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-07-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2021.675608/full |
| _version_ | 1818934459491155968 |
|---|---|
| author | Hao Yi-Dan Zhao Ying-Xin Yang Shi-Wei Zhou Yu-Jie |
| author_facet | Hao Yi-Dan Zhao Ying-Xin Yang Shi-Wei Zhou Yu-Jie |
| author_sort | Hao Yi-Dan |
| collection | DOAJ |
| description | The purpose of this review is to bridge the gap between clinical and basic research through providing a comprehensive and concise description of the cellular and molecular aspects of cardioprotective mechanisms and a critical evaluation of the clinical evidence of high-energy phosphates (HEPs) in ischemic heart disease (IHD). According to the well-documented physiological, pathophysiological and pharmacological properties of HEPs, exogenous creatine phosphate (CrP) may be considered as an ideal metabolic regulator. It plays cardioprotection roles from upstream to downstream of myocardial ischemia through multiple complex mechanisms, including but not limited to replenishment of cellular energy. Although exogenous CrP administration has not been shown to improve long-term survival, the beneficial effects on multiple secondary but important outcomes and short-term survival are concordant with its pathophysiological and pharmacological effects. There is urgent need for high-quality multicentre RCTs to confirm long-term survival improvement in the future. |
| first_indexed | 2024-12-20T05:04:37Z |
| format | Article |
| id | doaj.art-ea932d4e033549f4bff3d5374c7686b0 |
| institution | Directory Open Access Journal |
| issn | 2297-055X |
| language | English |
| last_indexed | 2024-12-20T05:04:37Z |
| publishDate | 2021-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cardiovascular Medicine |
| spelling | doaj.art-ea932d4e033549f4bff3d5374c7686b02022-12-21T19:52:28ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2021-07-01810.3389/fcvm.2021.675608675608High-Energy Phosphates and Ischemic Heart Disease: From Bench to BedsideHao Yi-DanZhao Ying-XinYang Shi-WeiZhou Yu-JieThe purpose of this review is to bridge the gap between clinical and basic research through providing a comprehensive and concise description of the cellular and molecular aspects of cardioprotective mechanisms and a critical evaluation of the clinical evidence of high-energy phosphates (HEPs) in ischemic heart disease (IHD). According to the well-documented physiological, pathophysiological and pharmacological properties of HEPs, exogenous creatine phosphate (CrP) may be considered as an ideal metabolic regulator. It plays cardioprotection roles from upstream to downstream of myocardial ischemia through multiple complex mechanisms, including but not limited to replenishment of cellular energy. Although exogenous CrP administration has not been shown to improve long-term survival, the beneficial effects on multiple secondary but important outcomes and short-term survival are concordant with its pathophysiological and pharmacological effects. There is urgent need for high-quality multicentre RCTs to confirm long-term survival improvement in the future.https://www.frontiersin.org/articles/10.3389/fcvm.2021.675608/fullhigh-energy phosphatescreatine phosphateenergy metabolismischemic heart diseasecardioprotection |
| spellingShingle | Hao Yi-Dan Zhao Ying-Xin Yang Shi-Wei Zhou Yu-Jie High-Energy Phosphates and Ischemic Heart Disease: From Bench to Bedside Frontiers in Cardiovascular Medicine high-energy phosphates creatine phosphate energy metabolism ischemic heart disease cardioprotection |
| title | High-Energy Phosphates and Ischemic Heart Disease: From Bench to Bedside |
| title_full | High-Energy Phosphates and Ischemic Heart Disease: From Bench to Bedside |
| title_fullStr | High-Energy Phosphates and Ischemic Heart Disease: From Bench to Bedside |
| title_full_unstemmed | High-Energy Phosphates and Ischemic Heart Disease: From Bench to Bedside |
| title_short | High-Energy Phosphates and Ischemic Heart Disease: From Bench to Bedside |
| title_sort | high energy phosphates and ischemic heart disease from bench to bedside |
| topic | high-energy phosphates creatine phosphate energy metabolism ischemic heart disease cardioprotection |
| url | https://www.frontiersin.org/articles/10.3389/fcvm.2021.675608/full |
| work_keys_str_mv | AT haoyidan highenergyphosphatesandischemicheartdiseasefrombenchtobedside AT zhaoyingxin highenergyphosphatesandischemicheartdiseasefrombenchtobedside AT yangshiwei highenergyphosphatesandischemicheartdiseasefrombenchtobedside AT zhouyujie highenergyphosphatesandischemicheartdiseasefrombenchtobedside |